Kadcyla Positioned For Wide Use In Metastatic Breast Cancer
This article was originally published in The Pink Sheet Daily
Roche is set to launch T-DM1 at the price of $9,800 a month, similar to cost of the preferred first-line regimen, which includes a combination of its own Perjeta and Herceptin. Drug was tested mostly in second-line HER-2 positive mBC, but labeling allows first-line treatment in a subset of patients at high risk.
You may also be interested in...
India’s Biocon Wins 1st Biosimilar Approval Of Herceptin; Will Launch Before March 2014
As the decks are cleared for an India launch of trastuzumab, Biocon and its global partner Mylan will be watched closely by both local and global competitors. The market impact in India will be most significant in terms of price, and it will test if Roche has played its cards right by aligning with local company Emcure.
Celltrion Files For Korea Approval Of Herceptin Biosimilar
Amid M&A talks and expectations for imminent European approval of a Remicade biosimilar, Celltrion becomes the first company to file for regulatory approval of a biosimilar of Roche’s blockbuster breast cancer therapy trastuzumab.
Roche’s Oncology Output Could Lead To Reimbursement Problems Down The Line
Roche posted solid 2012 results and development of new cancer drugs continues apace, forecasting further sales and profit gains in 2013 and beyond – as long as government insurers can handle the abundance.